Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 6 of 15

 
 

Novo Nordisk A/S (NYSE:NVO)

Consensus Rating
Moderate Buy
Rating Score
2.9
Ratings Breakdown
6 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$144.50 (42.0% Upside)

About Novo Nordisk A/S

Novo Nordisk A/S logoNovo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
11/6/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
10/17/2024BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$160.00 ➝ $156.00
10/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
8/19/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
8/8/2024BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$170.00 ➝ $160.00
8/5/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
7/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
6/25/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$163.00 ➝ $163.00
 

Shocking footage from Bill Gates’ $100,000,000,000 AI Bet (Ad)

If you missed out on Nvidia, watch this BEFORE November 19th.

Click here for the full video